In tumors, AS favors targeted therapy evasion and is one of the mechanisms that has been involved in loss or altered expression of CD19 leading to ALL escape from CAR-T anti-CD19 therapy (28). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.